TriSalus Life Sciences, Inc. - Common Stock (TLSI)

Sales rep productivity in new territories is running behind plan, so the growth case hinges on whether those reps catch up.

Sales ramp lagged plans despite new TriNav Advance clearance.

TriSalus Life Sciences (NASDAQ:TLSI) reported third-quarter revenue growth of 11% but updated its full-year outlook as newly added sales territories took longer than expected to become productive. The company also cited a faster-than-anticipated shift toward a liver cancer treatment technique invol

TriSalus Life Sciences (NASDAQ:TLSI) outlined its commercial expansion, product pipeline and clinical-evidence strategy during Canaccord Genuity’s Global Growth Conference, with management emphasizing the company’s pressure-enabled delivery technology for solid-tumor treatments. President and CEO M

TriSalus Life Sciences (NASDAQ:TLSI) reported second-quarter revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, as demand for its TriNav pressure-enabled drug delivery system increased. The company reiterated its full-year 2026 revenue outlook of $54 million to $57 million, represe

TriSalus (TLSI) Q1 2026 Earnings Transcript

TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device. President and Chief Executive Officer M

TriSalus (TLSI) Q4 2025 Earnings Call Transcript

TriSalus Q3 2025 results show strong 57% revenue growth but a wider-than-expected EPS loss. The company reaffirmed its 50% full-year growth outlook.

TriSalus (TLSI) Q3 2025 Earnings Call Transcript

TriSalus Life Sciences reports strong Q2 2025 revenue growth of 52% YoY to $11.2M, beating estimates. Losses narrow as commercialization of TriNav and PEDD platform gains momentum.